Lumos Diagnostics (ASX:LDX) partnered with MedPro Associates to provide national contract sales coverage for its point-of-care test, FebriDx, across hospital and primary care markets in the US, according to a Monday filing with the Australian bourse.
MedPro will provide over 60 territory representatives to increase awareness and adoption of the FebriDx technology designed to differentiate between bacterial and non-bacterial infections, the filing said.
Financial terms of the collaboration were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.